Development of Novel Tools to Study and Combat Pathogenic Microbial Biofilms by Erickson, Joshua
 Development of Novel Tools to Study and Combat Pathogenic  
Microbial Biofilms 
 
 
 
 
 
A THESIS  
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL  
OF THE UNIVERSITY OF MINNESOTA 
BY 
 
 
 
 
    
 Joshua D. Erickson 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF 
MASTER OF SCIENCE  
 
 
 
 
 
Dr. Christine Salomon 
 
 
 
 
 
December 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Joshua D. Erickson 2014 
ALL RIGHTS RESERVED
	  
i	  
ACKNOWLEDGEMENTS 
 
 I would like to first thank my advisor Dr. Christine Salomon for her amazing 
support, counsel, and direction throughout the course of this thesis project.  I would also 
like to thank my committee members Dr. Gary Dunny and Dr. Claudia Schmidt-dannert 
for their invaluable input and advice regarding this work.  I also want to thank my lab 
members for their relationships and help along the way. A special thanks goes to Jon 
Henrikson for his mentorship and aid with a number of these projects. 
 I also want to thank the group at Ecolab for the opportunity to work on a 
collaborative project with them. A special thanks to Dr. Heidi Hau, Dr. Duc Nguyen, and 
Cari Lingle for their leadership and guidance throughout the project.  
 Finally, I would like to thank my family for their support over the years. My Wife 
Megan has been by my side the entire way providing support and love to help me 
accomplish my goals. My parents have shaped me into the person I am today, and I 
cannot thank them enough for their financial and personal support.  
 
 
 
 
 
 
 
 
	  
ii	  
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS .............................................................................................. I 
TABLE OF CONTENTS .................................................................................................. II 
LIST OF TABLES ............................................................................................................ IV 
LIST OF FIGURES .......................................................................................................... V 
ABSTRACT ...................................................................................................................... VII 
1.         INTRODUCTION ................................................................................................ 1 
2. DESIGN OF A NOVEL LAMINAR FLOW BIOFILM REACTOR FOR IN-
VITRO ANTIMICROBIAL EFFICACY TESTING ........................................... 7 
 
 Introduction  .......................................................................................................... 7  
Materials and Methods .......................................................................................... 11 
   Strains and growth conditions ............................................................................ 11 
   MultiRep biofilm reactor method ...................................................................... 12 
Reactor preparation ................................................................................... 12 
            Reactor inoculation ................................................................................... 12 
            Continuous flow phase .............................................................................. 13 
   Crystal violet assay ............................................................................................ 13 
   XTT assay .......................................................................................................... 14 
   CFU enumeration ............................................................................................... 14 
   Reynolds number calculation ............................................................................. 15 
   Statistical analysis .............................................................................................. 16 
Results and Discussion ......................................................................................... 16 
               Design of the MultiRep reactor 
               Uniformity of biofilm growth in the MultiRep Reactor .................................... 17 
               Validation testing for MultiRep reactor   ........................................................... 19 
               Subsequent anti-biofilm testing in a 96-well plate ............................................ 22 
   Time and cost comparison of the MultiRep reactor and the Drip Flow reactor 23 
Conclusion ............................................................................................................ 24 
 
3. ENGINEERING A PROBIOTIC MICROBE TO TARGET AND DESTROY 
PSEUDOMONAS AERUGINOSA BIOFILMS ..................................................... 25 
 Introduction ........................................................................................................... 25 
Materials and Methods .......................................................................................... 34 
   Bacterial strains and plasmids ............................................................................ 34 
   Basic genetic techniques and enzymes .............................................................. 37 
   Construction of plasmids ................................................................................... 37 
   Construction of the binding cassette .................................................................. 37 
	  
iii	  
   Construction of pJE7 and pJEGFPsp ................................................................. 38 
   Characterization of nisin induction .................................................................... 39 
   Protein characterization ..................................................................................... 39 
   Quantification of alginate .................................................................................. 40 
   Characterization of binding to P. aeruginosa biofilms ...................................... 40 
                        P. aeruginosa growth in MultiRep reactor ............................................... 40 
                        P. aeruginosa growth in 96-well plate ...................................................... 41 
Preparation of L. lactis cells for binding studies ....................................... 41 
   Fluorescence microscopy ................................................................................... 42 
   Quantitative binding assay ................................................................................. 42 
   Preliminary testing of LAB strains against P. aeruginosa biofilms .................. 43 
                        Lactobacillus sp. supernatant and cell culture study ................................ 43 
L. plantarum and tobramycin study against P. aeruginosa biofilms ........ 44 
Results and Discussion ......................................................................................... 44 
               Characterization of the engineered L. lactis strain ............................................. 44 
                        Genetic construction of the binding cassette ............................................ 44 
                        Characterization of nisin induction ........................................................... 45 
                        Characterization of protein expression ..................................................... 46 
                        Attachment to Pseudomonas aeruginosa biofilms ................................... 48 
                        Growth rate of induced L. lactis strains .................................................... 52 
               Preliminary testing of LAB strains against P. aeruginosa biofilms .................. 53 
Conclusion ............................................................................................................ 57 
 
4.         FUTURE DIRECTIONS AND CONCLUSIONS ............................................... 58 
REFERENECES ............................................................................................................... 63 
APPENDIX ....................................................................................................................... 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
iv	  
LIST OF TABLES 
Table 
2.1       ASTM Standard methods for biofilm growth ....................................................... 10 
3.1       Strains and plasmids ............................................................................................. 35 
3.2       Primer sequences .................................................................................................. 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
v	  
LIST OF FIGURES 
Figure 
2.1.       Schematic diagram of the drip flow biofilm reactor ............................................ 11 
2.2.       Image of the MultiRep reactor system setup ....................................................... 13  
2.3.       Image of the MultiRep reactor ............................................................................. 17 
 
2.4.       Images of biofilm growth on steel discs .............................................................. 18 
 
2.5        Quantification of biofilm mass produced from growth in MultiRep ................... 18 
 
2.6        Quantification of biofilm mass and cell viability across channels ...................... 20 
 
2.7.       Quantification of biofilm mass and cell viability for rows of the reactor ............ 21 
 
2.8.       Subsequent anti-biofilm testing in a 96-well plate .............................................. 23 
 
3.1.       Illustration of the sortase-dependent anchoring in Gram-positive bacteria ......... 31 
3.2.       Binding cassette construct .................................................................................... 45 
3.3.  Effect of nisin concentration on GFP expression and cell density for L. lactis 
(pJE7) .................................................................................................................... 46 
 
3.4.       LDS-PAGE separation of membrane fractions .................................................... 47 
 
3.5.       Characterization of attachment to P. aeruginosa biofilms on steel discs ............ 49 
 
3.6.       Quantitative binding assay – biofilm grown in 96 well plate .............................. 50 
 
3.7.       Quatitative binding assay – biofilm grown in MultiRep reactor ......................... 51 
 
3.8.       Growth rate of L. lactis strains over time ............................................................ 52 
 
3.9.       L. plantarum supernatant effect on P. aeruginosa PAO26 biofilms ................... 54 
 
3.10.     Removal of P. aeruginosa PAO26 biofilms with L. plantarum cell cultures ...... 55 
 
3.11.     Tobramycin and L. plantarum cell cultures against P. aeruginosa biofilms ....... 57 
 
4.1.       CES-254 supernatant and CuSO4 activity against C. albicans biofilms ............. 61 
 
	  
vi	  
S1         Correlation of XTT absorbance to P. aeruginosa CFU enumeration recovered . 73 
 
S2.        Carbazole Standard Curve ................................................................................... 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
vii	  
ABSTRACT 
An increase in antibiotic resistance along with a decrease in antimicrobial 
products coming to market has compounded into a global issue that must be addressed. 
Biofilms are a morphological state of many pathogenic microbes that significantly 
augments their resistance to antimicrobial agents. Today, there is a need not only for 
groundbreaking strategies that are effective against drug resistant pathogens in their 
biofilm form, but also for tools to efficiently grow reproducible biofilms for development 
of anti-biofilm products.  In this work, the design of a novel reactor for biofilm testing 
and the development of a model live biotherapeutic product that targets and delivers 
antimicrobial products to specific biofilms are described. The biofilm reactor is a high-
throughput laminar flow reactor that is capable of producing uniform biofilm on surfaces 
for efficient subsequent testing. The live biotherapeutic is an engineered strain of 
Lactococcus lactis that specifically attaches to Pseudomonas aeruginosa biofilm 
structures using surface display technology. Preliminary testing was performed to 
characterize the anti-biofilm properties of multiple wild-type lactic acid bacteria (LAB) 
strains in order to choose the most effective strains for further development of the anti-
biofilm component.
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CHAPTER 1 
INTRODUCTION 
 Antimicrobial resistance has the potential to be one of the most significant public 
health issues of the twenty-first century.  The World Health Organization (WHO) has 
recently released a global report on antibiotic resistance and stated, “The problem is so 
serious that it threatens the achievements of modern medicine (WHO, 2014).” The Center 
for disease control (CDC) estimates that resistant microbes are the cause of over 2 million 
infections and approximately 23,000 deaths in the United States per year (CDC, 2013).  
Further compounding the issue is the dearth of new antimicrobial treatments that are 
coming to market.  As of 2013, only 2 new antimicrobial drugs had been approved since 
2009, and the number of drugs coming to the clinic continues to decline (Boucher, 2013).  
Considering the weight of this issue, there is a global responsibility to develop new 
antimicrobial therapies that will combat the widespread increase in antibiotic resistance.   
 One characteristic trait of many drug resistant microbes is their ability to form 
biofilms. Biofilms are complex communities of microbial cells that are attached to a 
surface.  The microbial cells encase themselves in a self-organized extracellular 
polymeric substance (EPS) that is primarily composed of proteins, polysaccharides, and 
extracellular DNA (eDNA) (Mann, 2012).  When these organisms attach to a surface and 
encase themselves in a biofilm they are more protected from the immune response 
(Jensen et al., 2010) and external stresses such as antibiotics, chemicals and physical 
challenges (Mah and O’Toole, 2001).  In fact, microorganisms in their biofilm state have 
been found to be 10 to 1000 times more resistant to antimicrobial treatment than 
planktonic cells (Nickel, 1985; Prosser, 1987).   
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Biofilm-associated antibiotic resistance is multifactorial and varies among 
different organisms. However, there are a few common resistance mechanisms that many 
biofilm-producing organism possess.  The first is the physical protection that the EPS 
matrix provides for the internal cells.  This matrix has been found to slow the diffusion of 
antibiotics by a factor of 2-3 (Cheema, 1986; Gordon, 1988). This slowed diffusion alone 
is not enough to account for the drastic increase in resistance, but the combination of 
enzymatic or chemical inactivation of the antibiotic within the matrix and the slowed 
diffusion may account for the increased resistance (Anderl, 2000).  The integrity of the 
biofilm matrix is indeed important, as disruption of the matrix has been shown to reverse 
antibiotic resistance of biofilm microbes (Misagh, 2009).  Other biofilm-associated 
resistance mechanisms may include adaptive response to altered environmental 
conditions (upregulation of stress-response genes), establishment of persister cells, and 
microenvironment gradients within the biofilm (low pH, low pO2, high pCO2, and low 
hydration) (Mah and O’Toole, 2001; Pozo and Patel, 2007; Stewart, 2002). It is likely 
that the enhanced resistance of microbial biofilms is due to a combination of mechanisms 
that creates a compounded effect.   
The economic cost of microbial biofilms is staggering. The Center for Disease 
Control states that over two thirds of human microbial infections are estimated to be 
related to the presence of biofilms (Donlan, 2002). While the NIH estimates this number 
to be even higher, stating that over 80% of microbial infections are caused by organisms 
growing as biofilms (NIH, 1998). Although it is difficult to quantify, the estimated 
economic cost of microbial biofilms is consistently in the high billions per year in the US 
alone.  In 2009 the CDC stated that Hospital acquired infections (HAI) cost from $35.7 to 
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$45 billion in the US (Scott, 2009).  If 80% of these infections were biofilm related, that 
would result in a cost of $28.6 to $36 billion for HAI biofilm-related infections per year 
in the US.  Biofilms related to implantable medical devices alone have been shown to 
cost the us health care system $3 billion dollars each year (Darouiche, 2004).  The 
financial burden of biofilms in industrial settings is even higher.  It is estimated that 
biofouling and biocorrosion in industrial systems cost approximately $200 billion per 
year in the US alone (Okabe, 1994).  Considering the threat to human health and the 
financial burden of microbial biofilms, it is critical that new strategies be developed to 
combat and control them.  The goal of this work was to develop novel tools for biofilm 
testing and design novel antimicrobial therapeutic strategies against microbial biofilms.   
 One requirement in the development of any anti-biofilm strategy is the 
reproducible growth of the biofilm in vitro.  The conditions that are used to grow the 
biofilm have a significant impact on the architecture of the biofilm and the performance 
of the antimicrobial therapies.  Particularly, the fluid dynamics of the system and the 
surface that the biofilm is grown on has a major impact on biofilm growth and resistance 
to antimicrobials. Therefore, it is critical that the laboratory conditions of biofilm growth 
be similar to the environmental conditions where the antimicrobial will be applied 
(Buckingham-Meyer, 2007).  In order to create the dynamic flow conditions of the true 
environment, an apparatus or reactor must be utilized.  There are a number of biofilm 
reactors that are currently available to grow biofilms under different fluid flow conditions 
(Lebeaux, 2013; Buckingham-Meyer, 2007).  The American Society for Testing and 
Materials International (ASTM) has outlined standard methods for use of the drip flow 
reactor for biofilm growth at the air/water interface under laminar flow conditions 
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(ASTM E2647-08).  This drip flow reactor has been recommended to model multiple 
disease states such as chronic wound infections, lung infections, and urological 
infections.  However, the current drip flow reactor is only capable of low throughput 
testing (4 coupons per growth cycle), and the biofilm growth on each coupon is not 
uniform. Therefore, the design of a novel laminar-flow biofilm reactor that yields 
uniform, high-throughput biofilm growth would be advantageous for the design of new 
anti-biofilm treatments.  Here the design of a novel laminar flow biofilm reactor that is 
high-throughput and produces uniform biofilms will be discussed. 
Many of the current treatment options for biofilm infections are not effective.  
There is a need for groundbreaking strategies that target the source of the problem, and 
go beyond conventional treatments.  New strategies such as microbial and cell-based 
therapeutics have the potential to mitigate this issue. With the advent of synthetic biology 
we now have the tools to create live bio-therapeutic products that will surpass the 
functions of small molecules and biologics to solve unmet medical problems.  Here we 
propose a novel strategy that utilizes a probiotic microorganism to target and deliver 
antimicrobial products to pathogenic biofilms.  This task is broken down into two 
components.  The first component involves the design of a lactic acid bacterial (LAB) 
strain that will specifically bind to P. aeruginosa biofilms.  The second component 
involves the engineering of this LAB strain for production of an anti-biofilm therapeutic 
only in the presence of P. aeruginosa biofilms.  Although these two components 
represent the complete vision of this project, the bulk of this work was performed on the 
development of the binding component.  Preliminary testing surrounding the second 
component will be discussed along with ideas for future development.  
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Bacterial surface display was utilized to accomplish the first task of enabling the 
probiotic bacterium to attach to Pseudomonas biofilms.  Surface display involves the 
fusion of a protein of interest to a cell membrane protein that is native to bacterial cells. 
This enables the protein of interest to be displayed on the cell membrane.  The protein of 
interest for this project is an antibody single-chain variable fragment (scFv) that was 
found to bind specifically to P. aeruginosa alginate (Pier, 2004).  The cell membrane 
protein chosen is a sortase-dependent cell membrane protein of Lactobacillus plantarum. 
These genes were fused and added to an E. coli/LAB shuttle vector and regulated under a 
nisin inducible promoter.  The characterization of this engineered LAB strain binding to 
Pseudomonas biofilms is discussed in Chapter 3.  
The second component will require the addition of genetic machinery that will 
enable the engineered strain to produce an anti-biofilm therapeutic in the presence of P. 
aeruginosa biofilms.  The therapeutic product will disrupt/inhibit P. aeruginosa biofilms, 
and the production of this product will be under the regulation of a P. aeruginosa 
promoter.  This regulation will ensure that the anti-biofilm therapeutic is only produced 
in the presence of P. aeruginosa (Saeidi, 2011).  This protein could be a biofilm-
disrupting enzyme such as a DNase or an alginate lyase, and/or it could be an 
antimicrobial peptide that kills P. aeruginosa cells.  Preliminary testing was performed 
with a combination of Lactobacillus plantarum cells and supernatant, alginate lyase, and 
tobramycin against a clinical strain of P. aeruginosa. 
Fungal biofilms are also a major concern in public health as the number of anti-
fungal agents capable of killing these organisms is small and continually declining.  
Fluconazole resistant Candida albicans is listed by the CDC as one of the major current 
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infectious disease threats to our society (CDC, 2013).  There is a need to develop new 
anti-fungal agents, or implement new strategies that are effective against fungal 
pathogens not only in their planktonic form, but also in their biofilm form. Here an 
isolated Streptomyces bacterium from the Soudan mine was found to produce a suite of 
natural products that were found to be synergistic with copper against C. albicans 
biofilms and planktonic cells. This project will be discussed briefly in Chapter 4.  
The following two chapters will include separate background information, 
materials and methods, results, and discussion sections.  Chapter 2 will begin with a 
description of the biofilm reactor that was designed, and the initial validation testing that 
was performed.  Chapter 3 covers the work that was performed in the development of a 
microbial therapeutic that targets P. aeruginosa biofilms. Finally, Chapter 4 will 
conclude and cover future directions along with potential applications of each of the 
developments from this thesis. 
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CHAPTER 2 
DESIGN OF A NOVEL LAMINAR FLOW BIOFILM REACTOR FOR IN-VITRO 
ANTIMICROBIAL EFFICACY TESTING  
 
Introduction 
Biofilm testing is a field of research that is relatively new to microbiology.  In the 
early 20th century, during the time of Robert Koch, a “pure culture” paradigm was 
established in which microorganisms were studied almost exclusively in free-living, 
planktonic cell cultures.  This became the standard, and was ingrained into microbiology 
and medicine for many years to come.  In the mid 20th century Arthur Henrici and others 
began to realize that the vast majority of microbes in the natural environment resided as 
communities attached to surfaces and surrounded themselves by a slimy material.  Not 
until the end of the 20th century did the importance of studying microbes in biofilm-form 
become firmly established. Now it is known that biofilm-associated bacteria are 
physiologically different, and are much more resistant to antimicrobial treatment than 
planktonic bacteria (Cunningham, 2005).  
In order to test antimicrobial agents against biofilm-associated bacteria, specific 
biofilm test methods must be designed.  Biofilm test methods can be broken down into 
subcategories of biofilm growth, treatment, sampling, and analysis.  It is important that 
each of these categories be compatible.  For example, the size and material of the coupon 
that the biofilm is grown on can have an impact on the treatment options.  Additionally, 
the method used to grow the biofilm may limit the options that are available for analysis.  
Ideally, the method used to grow the biofilm should represent the environmental 
conditions of interest, while enabling efficient treatment and analysis options.  In order 
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for a method to be useful by a wide audience it should be affordable, not require a high 
level of specialized training, be performed with readily available laboratory equipment, 
and be compatible with biosafety concerns (Parshionikar et al., 2009).  
Laboratory biofilm reactors are commonly used tools in biofilm research.  They 
are necessary to create a specific aquatic environment for the biofilm to grow.  The 
conditions that are used to grow the biofilm have a significant impact on the architecture 
and resistance of biofilms.  For example, a Pseudomonas fluorescens biofilm grown 
under high-shear conditions was much denser and more tightly attached to the surface 
than a P. fluorescens biofilm grown under low-shear conditions (Pereira, 2002).  
Additionally, a significant difference in colony forming unit (CFU) log reduction of 
antimicrobial agents was found when P. aeruginosa and S. aureus biofilms were grown 
under high-shear, low-shear, or static conditions (Buckingham-Meyer, 2007).  Therefore, 
when testing antimicrobial efficacy against a biofilm, it is critical that the laboratory 
conditions used to grow the biofilm be similar to the environment in which the 
antimicrobial will be applied.  
There are a number of different biofilm reactors that have been developed for use 
in a wide range of applications. Two primary categories of biofilm reactors are those used 
for bioremediation and those used for antimicrobial efficacy testing.  The focus of this 
chapter will be only on biofilm reactors designed for antimicrobial efficacy testing. Two 
of the primary categories of biofilm growth for antimicrobial testing include either batch 
cultures or continuous flow systems.  A few batch culture systems include the Calgary 
device (Ceri et al., 1999), microtiter assay (O’Toole and Kolter, 1998), cover slip culture 
(Merritt et al., 2003), the colony biofilm (Anderl et al., 2000), and biofilm grown on a 
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coupon suspended in a batch culture (Yu et al., 1993). Batch culture systems are 
beneficial due to the ease of setup and are more amenable to high-throughput testing. A 
few of the most commonly used continuous flow reactor systems include: the flow cell 
(Stoodley and Warwood, 2003), annular reactor (Characklis, 1990), rotating disc reactor 
(Zelver et al., 1999), modified Robbins device (Kharazmi et al, 1999), drip flow reactor 
(Stewart, 2002), and biofilm grown in tubing (Sauer et al, 2002).  The advantage of a 
continuous flow reactor is that a steady state can be achieved (Goeres, 2006), along with 
providing a more accurate representation of many natural environments.  
Despite the fact that the importance of biofilm testing has been known for many 
years, standard operating procedures for biofilm testing are just beginning to be 
developed.  The primary reason for the development of many microbiological standard 
procedures is for antimicrobial efficacy testing claims that are obtained through 
registration with governmental regulatory agencies such as the EPA or FDA. These 
product claims are obtained by demonstrating specific antimicrobial efficacy against a 
panel of microbial pathogens. A number of standard methods have been developed that 
support disinfectant claims against planktonic cells, but standard methods that support 
biofilm claims are limited. The American society for Testing and Materials (ASTM) 
released a series of biofilm test methods in 2002-2011 (ASTM E2647-08, ASTM E2562-
12, ASTM E2799-12, ASTM E2196-07). Each of the ASTM methods was designed for 
biofilm growth under different conditions (For a description of each of the ASTM 
methods see Table 2.1). These ASTM methods are useful for standard testing, but 
generally do not support product efficacy claims with a governmental agency such as the 
EPA. The EPA, however, has just released the first SOPs for biofilm testing in August of 
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2013 that will support biofilm efficacy claims using the CDC reactor for biofilm growth 
(EPA MB-19-02, EPA MB-20-01). Recognizing that standardized biofilm testing is in 
the early stages of development, there is room for improvement of current methods and 
development of new biofilm growth methods that represent additional environments.  
Table 2.1. ASTM Standard methods for biofilm growth 
Method Reactor used Year published Growth conditions 
ASTM E2196-07 Rotating Disk 
Reactor 
2002 Submerged, Continuous 
flow, Medium-shear 
ASTM E2562-12 CDC Reactor 2007 Submerged, Continuous 
flow, High-shear 
ASTM E2647-08 Drip Flow Reactor 2008 Air/liquid interface, 
Continuous flow, 
Laminar flow/low-shear 
ASTM E2196-07 MBEC  2011 Batch culture, low to 
medium-shear 
 
 The purpose of this collaborative project between the University of Minnesota 
and Ecolab was to design improved biofilm test methods that could be used for product 
development of antimicrobial products in the food and beverage industry.  In order to 
create the proper biofilm growth conditions that represent the environment in which these 
products will be used, biofilm growth under laminar flow conditions at the air/water 
interface was determined to be the most accurate growth method. The biofilm reactor that 
fits these criteria is the drip flow reactor (ASTM E2647-08); however, this was 
determined to be insufficient for product development for a number of reasons.  First, the 
number of individual biofilm test replicates that can be produced from a single cycle of 
growth in this reactor is too low (4 coupons/growth cycle) (Figure 2.1).  Second, biofilm 
growth on each coupon is not uniform, which would result in statistically insignificant 
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comparisons of antimicrobial products. Additionally, the time required to grow the 
biofilm is too high for the number of replicates that are produced.  According to the 
published work on this reactor, the total time requirement is 13 h of active work that is 
distributed over a period of 5 days (Goeres, 2009) yielding 195 min of active 
work/coupon.  Here a novel laminar flow biofilm reactor (designated as the MultiRep 
reactor) that produces uniform biofilms at the air/water interface and yields high 
replicates per growth cycle was designed.  
 
 
   Figure 2.1. Schematic diagram of the drip flow  
   biofilm reactor (Goeres 2009).  
 
Materials and Methods 
Strains and growth conditions 
 For routine growth, Pseudomonas aeruginosa ATCC 15442 was taken from a 
frozen glycerol stock (-80°C) and plated on TSA.  Single colonies were used to inoculate 
trypticase soy broth (TSB) (30 g/L), and cultures were grown at 37°C for 18-24 h in a 
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shaker (200 rpm).  For growth in the MultiRep reactor, TSB media was made at a 
concentration of 6 g/L and the temperature was 23°C.  
MultiRep biofilm reactor method 
Reactor preparation: 
 Autoclaved stainless steel coupons (5 mm diameter) were rinsed twice with de-
ionized water and placed into the wells of the MultiRep reactor with a forceps.  The 
tubing was then assembled and attached to the reactor vessel and autoclaved.  Silicone 
tubing was used for the effluent port attachments (VWR 1/8” X 1/4” Cat. #89068-432) 
and the influent port attachments (Masterflex L/S 14 tubing Cat. # 96400-14).  This is the 
correct size tubing for the inlet and outlet adaptors of the reactor, and also enabled the 
low flow rate that was desired for the system.  A glass flow break was added to the 
system upstream from the peristaltic pump. Glass flasks (4 L) were used for nutrient 
supply and waste.  TSB medium (6 g/L) was autoclaved in 2 L volumes and added to the 
sterilized glass flask used for nutrient supply.  The waste flask was attached to a vacuum 
line in order to efficiently pull the waste media from the reactor (see Figure 2.2 for 
image of reactor system).  The system was set up inside of a biological safety hood with 
controlled airflow to minimize contamination.  
Reactor inoculation: 
 A 5 mL culture of P. aeruginosa (ATCC 15442) was inoculated with an isolated 
colony from trypticase soy agar (TSA).  The 5 mL culture was incubated overnight at 
37°C and 200 rpm for 18-24 h, and then diluted 1:10 into fresh TSB media.  The tubing 
on both the inlet and outlet ports of the reactor was clamped off and 4 mL of the diluted 
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culture was added to each test channel in the reactor.  The inoculated system was 
incubated at 23°C for 4 hours to allow the cells to adhere to the surface.  
Continuous flow phase:  
 The clamps were then removed from the tubing and the reactor was set to an 
angle by adding a 5 mm spacer underneath the inlet side of the reactor.  The pump used 
in this study was a MasterFlex Pump 3 (Model #7553-71) with an Easy Load II pump 
head (Model # 77202-60).  The pump speed was set at level 1, which resulted in a flow 
rate of ~ 0.7 mL/min.  The continuous flow system was then run for 24 hrs.  If the biofilm 
needed to be grown for a longer period of time (48 – 72 h), the waste was removed and 
sterile media was added to the feed flask every 24 hrs. 
     
 
Figure 2.2. Image of the MultiRep reactor system setup.  
Crystal violet assay: 
 This method was adapted from a previous method (O’Toole, 2011). Briefly, discs 
were transferred to a round bottom 96-well plate and washed 1x with 160 µL of sterile 
PBS (pH 7.2) using a multichannel pipette.  150 µL of crystal violet (0.1%) was then 
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added to each well.  Discs were soaked in crystal violet for 10-15 min, and washed 3x 
with 160 µL of PBS.  The discs were then transferred to clean wells and washed 1 final 
time with 160 µL of PBS.  160 µL of glacial acetic acid (30%) was then added to each of 
the wells and incubated at room temperature for 10-15 min.  Following this incubation 
period, the acetic acid solution was pipetted up and down 2 times and transferred to clean 
wells of a 96 well flat-bottom plate.  Absorbance was read in a Bio-Tek plate reader at 
550 nm.   
XTT assay:  
Following treatment of the discs, discs were transferred to a round bottom 96-well 
plate and washed 1x with 160 µL of sterile PBS (pH 7.2).  2,3-Bis-(2-Methoxy-4-Nitro-5-
Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) sodium salt (XTT) was added to warm 
PBS (55°C) at a concentration of 0.8 mg/mL.  This solution was vortexed and centrifuged 
for 1 minute to pellet the insoluble material.  Menadione was added to DMSO at a 
concentration of 0.2 mg/mL.  25 µL of the XTT solution, 1 µL of the menadione solution, 
and 74 µL PBS were added to each well of the plate.  The plate was incubated in the dark 
for a minimum of 6 h at 37°C.  Following the incubation period, the XTT solution was 
pipetted up and down twice and transferred to a new microtiter plate.  The absorbance 
was then read at 450 nm using a Bio-Tek plate reader.   (any concern about cell debris 
interfering with the absorbance readings?) 
CFU enumeration: 
 Following treatment of the discs, the discs were transferred to a round bottom 96-
well plate and washed 1x with sterile PBS (pH 7.2).  150 µL of sterile PBS was added to 
each well that contained a disc.  The plate was then sealed inside of a plastic bag, and 
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placed in a water bath sonicator (sonicated on high for 30 +/-5 min). A serial 10 fold 
dilution of each disc was then carried out in additional 96-well microtiter plates.  After 
sonication, the content of each well was pipetted up and down 2 times. Then, 100 µL 
from each well containing a disc was transferred to the top row of a sterile flat-bottom 
96-well microtiter plate.  180 µL of sterile PBS was added to each well in rows B-H of 
the plate.  The transferred 100 µL samples were then serial diluted (100 – 10-7) by 
transferring 20 µL from each well into the next using a multichannel pipette.  Each well 
was mixed by pipetting 2 times and swirling the pipette tips in the well a total of ten 
revolutions.  Fresh pipette tips were used for each subsequent transfer.  The contents of 
each dilution were then spot plated on TSA using a multichannel pipette by first mixing 
each well and spotting 10 µL of the sample onto the TSA.  Plates were incubated at 35°C 
+/- 2°C for 16-18 h. This method was adapted from the MBEC ASTM method (ASTM 
E2799-12).  
 Calculation of CFU/disc: 
  Log10(CFU/disc) = Log10[(A/B)(C)(D)] 
 Where: 
  A = CFU counted in the spot 
  B = Volume plated 
  C = Well volume 
  D = Dilution 
Reynolds number calculation: 
 Calculation of the Reynolds number for the MultiRep reactor was based on an 
equation developed for fluid flow through an inclined plane channel (Bird et al, 2002). 
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The calculations were based on the bulk fluid being water at 20°C. The fluid flow was 
determined to be 0.7 mL min-1. The fluid thickness was determined to be 1.2 mm based 
on the flow rate and the geometry of the channel.   
Statistical analysis 
 The data generated from the crystal violet assay, XTT assay, and CFU 
enumeration was statistically analyzed using a one-way ANOVA test. The results were 
generated with 3 degrees of freedom between groups, and 28 degrees of freedom within 
groups for the comparison of the channels. For the comparison of the rows, the results 
were generated with 7 degrees of freedom between groups, and 28 degrees of freedom 
within groups.  
 
Results and Discussion 
Design of the MultiRep reactor 
 A novel laminar flow biofilm reactor that produces a uniform biofilm at the 
air/water interface was designed (Figure 2.3). The initial design of the reactor was made 
using Google SketchUp. The first series of prototypes were 3D printed with a variety of 
plastics.  Multiple adjustments were made to the initial design to optimize uniform 
biofilm growth over the coupon surface. 3D printing was not ideal for the end product 
due to the porosity that results from the layering of the plastic material that ‘builds’ the 
object.  The final model (made in SolidWorks) was CNC machined out of an 
autoclavable medical grade plastic. The material is not compromised after repeated 
autoclaving procedures.  Further, sterility testing revealed that the device is sterile after 
autoclaving for 15 min at 121°C using a dry cycle (data not shown). This reactor has 
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capacity to grow 80 biofilms on separate coupons during a single run (10 channels, with 8 
coupons per channel). The wells of the reactor are designed to accommodate coupons that 
are 5 mm in diameter. This size is ideal for transfer of the discs into a 96-well plate for 
subsequent testing. The Reynolds number was determined to be 29 when considering a 
flow rate of 0.70 mL/min, which is considered laminar flow. 
A            B 
     
Figure 2.3. Image of the MultiRep reactor.  Tope image without cover (A). The inlet 
ports are at the top of the reactor and the outlet ports are shown at the bottom of the 
reactor in this image.  There are 10 channels with 8 coupon wells in each channel.  Total 
coupon capacity is 80. Side image with cover (B). 
 
Uniformity of biofilm growth in the MultiRep Reactor 
 
 In the design of this biofilm reactor, one important characteristic was that a 
uniform biofilm could be produced over the surface of the coupons.  This is important 
because it maximizes the amount of biofilm on the coupon and minimizes variation 
between coupons. Figure 2.4 shows images of P. aeruginosa biofilm grown on stainless 
steel discs. Biofilms were grown on the discs in a microtiter plate, or in the MultiRep 
reactor and stained with crystal violet.  A uniform biofilm over the surface of the coupon 
could be achieved using the Multirep reactor (Figure 2.4C).  The biofilm produced on 
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the steel discs in the 96-well plate grew only around the periphery of the coupon (Figure 
2.4B).  Figure 2.5 shows a quantitative comparison of the amount of biofilm produced 
when grown in the MultiRep reactor compared to a microtiter plate. It is important to 
note that these two methods of growth are fundamentally different.  Growth in the 
microtiter plate is a batch, submerged culture, while growth in the MultiRep reactor is at 
the air/water interface with continuous flow conditions. However, this comparison does 
indicate that the MultiRep reactor is an effective tool for uniform, robust growth of P. 
aeruginosa biofilms at the air/water interface. 
A    B           C 
   
 
Figure 2.4. Images of biofilm growth on steel discs. Steel disc with no biofilm growth, 
negative control (A).  P. aeruginosa biofilm grown on steel disc in a 96-well microtiter 
plate for 48 h and stained with crystal violet (B).  P. aeruginosa biofilm grown on a steel 
disc in the MultiRep reactor for 48 h and stained with crystal violet (C). Discs are 5mm in 
diameter.   
 
 
Figure 2.5.  Quantification of biofilm mass produced from growth in MultiRep. 
Quantitative comparison of P. aeruginosa grown on steel discs in a microtiter plate or the 
MultiRep reactor for 24 h using the crystal violet assay. 
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Validation testing for MultiRep reactor  
 
 To determine if the coupon position has an effect on biofilm growth, a study was 
performed that compared two measurements of biofilm growth. The first was a 
measurement of biofilm mass that was produced on each disc using the crystal violet 
assay. In this test, the crystal violet stain absorbs into the biofilm matrix and cells, and is 
dissolved/extracted with an acid.  The resulting absorbance represents the amount of 
biofilm that was initially present (O’Toole, 2011). The second measurement of biofilm 
growth was cell viability.  For this measurement, both the XTT assay and CFU 
enumeration were performed. The XTT assay is a colorimetric test that detects 
metabolically active cells (Smith, 2008).  See the supplemental information section for 
data that shows the correlation between CFU and XTT absorbance for P. aeruginosa. 
Due to the peristaltic pump that was used for this study, only four channels were tested.  
This generated a sample population of 32 coupons (4 channels x 8 coupons/channel).  
The MultiRep reactor was capable of generating biofilms on each of the 32 coupons that 
were tested.  The biofilm growth across the four channels and down each row were 
analyzed and compared. 
The average values obtained for each channel are shown in Figure 2.6. The 
results for the crystal violet assay are shown in Figure 2.6A, and the results for the XTT 
assay and CFU enumeration are shown in Figure 2.6B. The data generated from these 
assays were statistically analyzed with an ANOVA test. The crystal violet, XTT, and 
CFU enumeration values statistically correlated and indicate that there was no difference 
between biofilm mass or cell viability across the channels. The crystal violet assay data 
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resulted in a p-value of 0.52, and the XTT assay resulted in a p-value of 0.65. Therefore, 
the coupon position across each channel has no statistically significant impact on biofilm 
growth.   
A               B 
  
Figure 2.6. Quantification of biofilm mass and cell viability across channels. Results 
from crystal violet (A) and XTT/CFU enumeration (B) assays following biofilm growth 
in the MultiRep reactor.  Crystal violet assay results indicating the biofilm mass on each 
steel disc (A).  XTT assay results (bars) indicating the abundance of viable cells 
recovered from each disc (A – left axis). The red squares are the average values obtained 
for CFU enumeration from each disc (B – right axis).  
 
 Next, a comparison of biofilm growth for each row of the reactor was performed. 
The data generated for this comparison is shown in Figure 2.7.  The crystal violet assay 
comparison of each row shows more variation than the comparison of each channel 
shown in Figure 2.6.  This is most likely due to each group in each row only having 4 
replicates, while each group per channel has 8 replicates. There appears to be a general 
trend downward from row number 1 to row number 8 in both biofilm mass and cell 
viability; however, this trend is not statistically significant for biofilm mass (p-value 
>0.05 for CV assay). This trend is likely due to the fact that the first row receives the 
fresh nutrient supply, while the last row receives a more depleted nutrient supply. 
Additional testing should be performed to fully characterize this effect down each 
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channel. Despite the slight decrease in biofilm growth as the coupon position moves 
away from the nutrient supply, it appears that each channel has this same variation.  
Therefore, a comparison of disinfectant efficacy can still be effectively made as long as 
each channel is used as a study group rather than each row.  
A                B 
  
Figure 2.7. Quantification of biofilm mass and cell viability for each row of the reactor. 
Crystal violet comparison of each row in the MultiRep reactor (A).  CFU enumeration 
comparison of each row in the MultiRep reactor (B). 
 
In order to properly validate this reactor for standard method use, additional 
testing would need to be provided.  According to the US Environmental Protection 
Agency regarding validation of microbiological methods of analysis, multiple method 
attributes would need characterization (Parshionikar et al., 2009). These attributes 
include specificity and sensitivity, precision, accuracy, limit of detection, and linearity. 
Specificity is the ability to differentiate between the target organism and other organisms, 
and sensitivity is the proportion of the target organism that can be detected. Precision is a 
variation of independent results that are obtained under specific conditions. This is 
broken down into both within-lab and between lab repeatability and reproducibility. 
Accuracy is the closeness of a test results to that of an accepted reference value. Limit of 
detection is the minimum amount of test substance that can be detected.  Finally, linearity 
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is the ability of the method to produce results within a set range and is directly 
proportional to the concentration of a test substance (Parshionikar et al., 2009). The 
validation of these attributes for the MultiRep reactor was not yet performed due to time 
constraints.  
As mentioned in the introductory section of this chapter, the EPA has only 
released a method regarding the CDC biofilm reactor (EPA MB-19-02).  To date, there is 
no EPA method released for the drip flow reactor (ASTM E2647-08).  The low 
replication of this reactor (4/growth cycle) may be a limiting factor for use of this reactor 
in an EPA method for biofilm growth under laminar flow conditions at the air/water 
interface.  The MultiRep reactor; however, with much higher replication (80/growth 
cycle) and uniform biofilm growth over the surface of the coupon holds significant 
promise for standard method development.    
 
Subsequent anti-biofilm testing in a 96-well plate 
As mentioned previously, the MultRep reactor is designed to accommodate 
coupons that are the proper size for transfer to a 96-well microtiter plate.  To demonstrate 
this utility, biofilms grown on steel discs in the MultiRep reactor were transferred to a 96-
well plate, treated with anti-microbial products provided by Ecolab, and compared using 
the XTT assay. From the total coupons used in this study, 4 (1 from each channel) were 
CFU enumerated, 4 (1 from each channel) were measured using the crystal violet assay, 
and 16 were used to compare the impact that multiple treatments had on cell viability. 
The CFU enumeration and crystal violet assays were performed to compare the starting 
CFU and biofilm mass from coupons across different channels. Figure 2.8 shows that 
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following biofilm growth in the MultiRep reactor, coupons can be transferred to a 96-
well plate, treated with antimicrobials (A, B, and D), and analyzed to differentiate the 
antimicrobial effect on the biofilm. This demonstrates the feasibility of this reactor for 
antimicrobial product development against microbial biofilms.  
 
Figure 2.8.  Subsequent anti-biofilm testing in a 96-well plate. Comparison of multiple 
treatments (provided by Ecolab) against P. aeruginosa biofilms using the XTT assay. 
 
 
Time and cost comparison of the MultiRep and the Drip Flow reactors 
 
 To determine the affordability of the MultiRep reactor, a cost comparison was 
made with the drip flow reactor.  The cost of the drip flow reactor is $998 from 
Biosurface Technologies Corporation. The rough cost estimate of the MultiRep reactor is 
$200.  Therefore, the cost per replicate ($998/4) for the drip flow reactor is ~ $250, while 
the cost per replicate ($200/80) for the MultiRep reactor is $2.50. The total time 
requirement for the drip flow reactor procedure is 13 h of active work that is distributed 
over a period of 5 days (Goeres, 2009), yielding 195 min of active work/coupon.  
Assuming that the MultiRep reactor would require around the same amount of time to 
perform the procedure; this would result in 9.75 min of active work/coupon.  Therefore, 
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the economic and time costs are substantially lower for the MultiRep reactor in 
comparison to the drip flow reactor.  
  
Conclusion  
 
 With a growing understanding of the importance of biofilms in antimicrobial 
efficacy testing there is a need for reactors that support biofilm growth under a wide 
range of conditions.  Current reactor options for continuous laminar flow biofilm growth 
at the air/water interface are limited to low replication and less than ideal biofilm 
uniformity over the surface of the coupon.  This results in a high cost per replicate along 
with a high time requirement per replicate.  In collaboration with Ecolab, we engineered a 
novel biofilm reactor that produces biofilm growth at the air/water interface under 
laminar flow conditions.  This reactor yields a high number of replicates per growth cycle 
with uniform biofilm growth over the surface of the coupon. The high replication per 
growth cycle drastically lowers the cost per replicate and the time required per replicate.  
The coupon position within this reactor was found to have no statistically significant 
impact on biofilm growth across each channel and the ease of subsequent testing in a 96-
well plate was demonstrated.  This reactor holds the potential to be used in a standard 
method for biofilm growth under laminar flow conditions at the air/water interface. The 
versatile utility of this reactor will be demonstrated in the following chapter through 
characterization of a live biotherapeutic agent that targets microbial biofilms.  
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CHAPTER 3  
ENGINEERING A PROBIOTIC MICROBE TO TARGET AND DESTROY 
PSEUDOMONAS AERUGINOSA BIOFILMS  
 
Introduction 
 Acute microbial infections in humans are primarily caused by free-living 
(planktonic) cells that rapidly replicate, while many chronic infections are due to the 
establishment of biofilms within the host (Furukawa et al., 2006). These chronic 
infections are especially concerning because they are often resistant to conventional 
antimicrobial strategies such as antibiotics. Chronic infections associated with cystic 
fibrosis patients, endocarditis, burn wounds, chronic prostatitis, otitis media, 
periodontitis, and in-dwelling medical devices are examples of disease states caused by 
biofilms that are of high concern in health care (Donlan, 2002).  
According to the CDC, gram-negative bacteria such as Pseudomonas, 
Acinetobacter, and Enterobacteriaceae are some of the most prominent concerns due to 
pan-resistance to nearly all the drugs that could be considered for treatment (CDC, 2013).  
These pathogens are notorious biofilm-forming microbes, and are known to have high-
levels of antimicrobial resistance especially in their biofilm state (Bales et al., 2013).  P. 
aeruginosa is a biofilm-forming opportunistic organism that plagues patients with 
immune-deficiencies such as cancer and cystic fibrosis (Saeidi et al., 2011). This 
organism is known to colonize and cause disease in burn wounds, respiratory, 
gastrointestinal, and urinary tracts (McCue and Kahan, 2006; Jensen et al., 2010).  
Notably, P. aeruginosa infections are the most common infection for patients that have 
been hospitalized for more than 1 week (McCue and Kahan, 2006).  
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The primary treatment option for P. aeruginosa infections is antibiotics. One 
challenge associated with antibiotic treatment for P. aeruginosa infections is that many 
strains are multi-drug resistant even in their planktonic form, and become even more 
drug-resistant in the biofilm state. This leads to a requirement for high doses of the 
antibiotics over long periods of time that can result in the selection of more resistant 
strains.  Further, treatment of P. aeruginosa infections with high doses of antibiotics, 
especially broad-spectrum antibiotics, can have a negative effect on the healthy human 
microbial flora leading to further issues such as chronic Clostridium difficile infections  
(Aloush, 2006).   
Bacteriophage therapy, the therapeutic use of bacteriophage for treatment of 
pathogenic bacterial infections (Darouiche, 2004), is another treatment that has been 
considered and tested extensively. Although it has a longer history than antibiotics, and 
can be effective against specific antibiotic resistant strains of bacteria even in their 
biofilm form, there are multiple important limitations to this therapy. First, phage therapy 
many times cannot be reapplied to a patient once antibodies have been raised against the 
virus (Hausler, 2006).  Second, to be effective, phage therapy requires very specific 
identification of the infectious organism in order to select the proper phage for treatment, 
which can be costly, unreliable, and require cocktails of bacteriophage (Keen, 2012). It is 
evident that current treatment options for biofilm-associated infections are limited, and 
there is a need for new strategies.  
Synthetic biology combines principles of biology and engineering to design and 
construct biological devices that serve useful purposes. The power of synthetic biology 
combined with a new understanding of the human microbiome has created a new area of 
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biopharmaceutical therapies called live biotherapeutic products (Olle, 2013).  This new, 
exciting field harnesses the ability that individual microbes and microbial communities 
have in the modulation of human health to solve medical problems that are otherwise 
untreatable. Our focus here will be on individual engineered microbes for therapeutic 
applications. 
These individual live biotherapeutic products or microbial therapeutics have 
multiple attributes that make them the ideal ‘robot factories’ for drug delivery (Forbes, 
2010). First, they have the capability of performing superior tasks compared to small 
molecules or biologics alone.  Not only can these microbial vehicles use small molecules 
and biologics as tools or weapons, but they can also deliver, produce and regulate the 
deployment of these accessories.  One major advantage of microbial therapies is that they 
are programmable.  Through manipulation of their genetic machinery, special functions 
can be added or taken away (Wang et al., 2013).  Additionally, many bacteria are motile 
and can sense stimuli within their environment and make adjustments accordingly.  This 
ability could be harnessed to enable intelligent delivery and production of drugs at hard to 
reach sites through signal recognition or production (Forbes, 2010).  Another advantage 
of microbial therapy is that microorganisms that normally inhabit human bodies can be 
utilized; thus minimizing the potential for an immune response to the treatment (Steidler 
and Rottiers, 2006).  
There are a few challenges to using bacteria as drug delivery vehicles that must be 
considered and addressed before these organisms can be used in the clinic.  One 
challenge is insuring that the organism is producing the drug at the proper dose.  It must 
be a high enough dose to perform its purpose against the pathogen, but it must not be too 
	  
28	  
high of a dose where it will be toxic to the host. Another challenge is that bacteria are 
prone to mutate, which could hinder the efficacy of the therapeutic organism. An 
additional concern is that the engineered microbes may escape into the environment 
(Steidler and Rottiers, 2006). This issue can be dealt with by designing the organism to 
have a ‘kill switch’ were it will be inactivated once its task has been implemented 
(Callura et al., 2010). Despite these challenges, the potential benefits of using microbes 
as therapeutics could outweigh the challenges.   
The use of engineered bacterial cells for therapeutic purposes has gained wide 
interest, and a number of groups have demonstrated and developed some of the key 
attributes of bacteria as therapeutic vehicles. Duan and March demonstrated that bacteria 
could modulate the virulence of pathogens through the production of signaling molecules 
by engineered probiotic organisms (Duan and March, 2010). Hwang, et al. have recently 
shown that bacterial chemotaxis can be programmed to direct probiotic organisms toward 
human pathogens and produce proteins that eradicate biofilms (Hwang et al., 2013). The 
Forbes lab is developing strains of bacteria that target cancerous tumors and are 
programmed to deploy proteins that kill the cancer cells once they are inside the tumor 
(Jean, 2014). There are also a few examples of companies that are developing microbial 
therapeutics. A company called Oragenics (http://www.oragenics.com/) has design a 
cavity prevention therapy that employs a novel strain of Streptococcus mutans that no 
longer produces lactic acid (lactis acid production lead to dental caries) and has a 
competitive advantage over wild-type S. mutans strains (Hillman, 2002). Another 
example, designed by a company called Osel (http://www.oselinc.com/), involves the 
prevention of HIV infections in females via an engineered Lactobacillus.  In this system, 
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the Lactobacillus is engineered to produce a HIV microbicide that will inhibit the virus as 
it enters the vagina (Lagenaur, 2011).    
The rapidly growing number of studies in the field suggests that microbial 
therapies hold great promise for application in human health. One additional component 
that could enhance some of the example systems discussed is the design of a probiotic 
organism that attaches to specific surfaces of interest for localized production of the 
therapeutic products.  To demonstrate this idea, and to provide a novel strategy against 
pathogenic biofilms, we chose to direct the attachment of a probiotic organism to the 
exopolysaccharide matrix of biofilms.  In this study, P. aeruginosa was chosen as the 
target pathogen because it is a model organism for biofilm testing and it is a gram-
negative pathogen of great concern in health care. L. lactis was chosen as the therapeutic 
vehicle because it is considered a GRAS (define) organism (FDA, 2014), it is motile, and 
the genetic manipulation has been well established (Mierau and Kleerebezem, 2005). 
Surface display has been used extensively in both phage and bacteria over the 
years for a wide range of applications in biotechnology. Phage display has been a 
fundamental tool in combinatorial protein engineering because it allows the phenotypic 
mutational optimization of a protein to be easily linked to the genotype of the protein 
(Rader and Barbas, 1997). The use of bacteria for surface display enables the display of 
larger proteins on the surface and broadens the potential applications such as vaccine-
delivery vehicles, antibody display for diagnostics, combinatorial protein engineering, 
whole-cell biocatalysis, and metal binding protein display (Wernerus, 2004; Bloois et al., 
2011).  The advantage of using bacteria as vaccine delivery vehicles is that the bacteria 
can greatly increase the half-life of the antigen in the host, and create a local immune 
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response near the mucosal surface of interest.  Antibody surface display can be combined 
with a vaccine delivery vector to enhance delivery to specific immunoreactive locations. 
Whole-cell biocatalysis has been used in industry as a cost effective method of 
immobilizing enzymes that perform specific industrially relevant reactions (Wernerus, 
2004).    
For our model system, a native cell-membrane protein found in L. plantarum was 
used to display and anchor the alginate-binding scFv protein on the cell membrane of the 
engineered lactic acid bacteria (LAB) strain.  In bacteria as a whole, surface proteins play 
an important role in mediating interactions with the environment. In LAB, the sortase 
enzyme is responsible for covalently attaching a subgroup of proteins called sortase 
dependent proteins (SDPs) to the cell membrane. This is a two-part process that involves 
both protein targeting to the membrane and covalent anchoring of the protein to the cell 
membrane. The targeting of the protein usually involves the secretory (Sec) pathway or 
the twin-arginine translocation (TAT) pathway. The Sec pathway appears to be much 
more common in LAB. In the Sec pathway, unfolded proteins that contain an N-terminal 
leader peptide, a hydrophobic core, and a specific C-terminal sequence that is recognized 
by the Sec machinery are targeted to the cell exterior (Call and Klaenhammer, 2013). One 
group of SDPs that are covalently attached to the cell membrane of LAB is the LPXTG-
anchored proteins.  These proteins contain a specific C-terminal motif (LPXTG), a 
positively charged tail, and a C-terminal hydrophobic region that is recognized by the 
sortase enzyme (Figure 3.1 A) (Call and Klaenhammer, 2013). However, it has been 
found that in most Lactobacilli the motif is actually LPQTXE (Kleerebezem et al., 2003), 
and this motif is also functional in Lactococcus spp. (Cortes-Perez et al., 2005).  
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Figure 3.1. Illustration of the sortase-dependent anchoring in Gram-positive bacteria.  (A) 
Shows the two components that are necessary for sortase anchoring, the signal peptide 
and the LPXTG motif.  (B) The signal peptide is important for localization to the 
membrane. The Sec system recognizes the signal peptide and exports the protein to the 
exterior (1). The sortase then recognizes the substrate (LPXTG)(2), cleaves between 
glycine and theonine (3), threonine then forms a bond with the pentapeptide crossbridge 
(4). Finally, the sortase substrate becomes part of the normal cell-wall construction 
(Reprinted with permission from Frontiers in Microbiology Journal (Call and 
Klaenhammer, 2013)).   
 
The cell-membrane protein used in this study is an LPQTXE-anchored SDP 
identified as lp_2578. Previously, this protein was used to display an oncofetal antigen 
(OFA) on the surface of L. plantarum for a mucosal cancer vaccine (Fredriksen et al., 
2010). To display the OFA on the cell membrane, the OFA gene was fused to the anchor 
sequence on the N-terminal side of both the hydrophobic region and the LPQTXE motif, 
but on the C-terminal side of the signal peptide. Fredriksen et al. compared the surface 
expression of this protein using a short, medium, or full-length anchor sequence. They 
found that the highest level of surface display was found with the truncated medium-
length anchor (Fredriksen et al., 2010).  Therefore, the medium truncated version was 
chosen for this study.  
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In designing the binding component of this project, it was important to target a 
unique biofilm component not commonly found in many biofilm structures to enable 
specific binding of the engineered LAB to the biofilm of interest even in the presence of 
other natural biofilms.  Mucoid strains of P. aeruginosa contain a unique EPS component 
called alginate. Alginate is a high-molecular weight polysaccharide composed of non-
repeating D-mannuronic acid and L-guluronic acid residues (Linker and Jones, 1964). It 
is only found in some brown algae species, and Azatobacter and Pseudomonas bacteria. 
The algal alginate is, however, different from the bacterial form in that the bacterial 
version is O-acetylated (Donati and Paoletti, 2009). 
Our system utilizes a short chain fragment variable (scFv) fragment derived from 
human monoclonal antibodies (mAbs) that bind to Pseudomonas alginate (Pier et al., 
2004). These mAbs mediated immunological killing of Pseudomonas mucoid strains as 
well as non-mucoid, low alginate producing strains.  One specific mAb (F429) was found 
to have the broadest overall alginate binding activity over the widest range of 
Pseudomonas isolates from cystic fibrosis patients.  For this project, we utilized the scFv 
region of the F429 mAb (Pier et al., 2004), and joined the VH and VL chains of the scFv 
with a linker peptide (GGGGS)3 that enables proper linkage and flexibility between the 
light and heavy chains of the scFv (Shen et al., 2008).  In order to display this alginate 
binding protein on the cell membrane, the synthesized F429 scFv DNA sequence was 
fused to the N terminal side of the SDP anchor peptide DNA sequence and C terminally 
to the signal peptide DNA sequence. This construct was then cloned into an E. coli/LAB 
shuttle vector and is regulated by a nisin inducible promoter.  
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The impetus for designing a microbe that can attach to biofilms is to ultimately 
inhibit or eradicate that biofilm through deployment of extracellular products. Five 
strategies have been suggested to treat biofilm-associated infection: substances able to 
destroy the biofilm matrix, substances that destroy persister cells, quorum-quenching 
enzymes, substances that cause biofilm self-destruction, and strategies to boost 
antimicrobial action (Del Pozo and Patel, 2007). With our system, any one of these 
strategies could be employed.  It is also possible that the probiotic strain could natively 
have the capability of inhibiting or destroying the biofilm. An L. plantarum supernatant 
was shown to inhibit P. aeruginosa through a quorum quenching mechanism (Ramos et 
al., 2012). Additionally, LAB strains are known to modulate the immune system in a 
number of ways (Matsuzaki and Chin, 2000; Wells, 2011) and prevent infections (Reid 
and Burton, 2002). It is possible that attachment of the probiotic organisms to the biofilm 
structures could enhance the immune systems ability to eradicate the infection. To 
enhance the native ability of the probiotic to eradicate biofilms, heterologous expression 
of anti-biofilm components could also be implemented. For example, alginate lyase and 
DNase, both alone and separately have been found to enhance the antibiotic killing of P. 
aeruginosa biofilm cells (Alipour et al., 2009). Additionally, high molecular weight 
protein antibiotics such as pyocin S2 that not only kill the pathogenic cells, but also 
destroy the biofilm matrix could be utilized (Smith et al., 2012).  
In this project, bacterial surface display was utilized to express the F429 scFv on 
the cell membrane of L. lactis by fusing it to a native LAB sortase-dependent cell 
membrane protein to enable the attachment of L. lactis to the biofilm structure of P. 
aeruginosa. The EPS component alginate was chosen as the target for binding because it 
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is a unique polysaccharide component not commonly found in microbial biofilms. P. 
aeruginosa was chosen as a target for binding because it is a model organism for biofilm 
testing and is a known antibiotic resistant human pathogen. This is a model system 
designed to test the feasibility of directing the attachment of probiotic cells to biofilm 
structures. Further, this is one tool in the overall goal of enhancing biofilm eradication by 
developing a microbial therapeutic that deploys anti-biofilm products at the location of 
the biofilm. The bulk of this chapter focuses on the binding aspect of this system, but 
preliminary testing was performed to characterize the effect that LAB strains alone and in 
combination with biofilm degrading enzymes have on P. aeruginosa biofilms.  
 
Materials and Methods 
Bacterial strains and plasmids 
 The bacterial strains and plasmids used in this study are listed in Table 3.1. 
Lactococcus lactis was cultured statically at 30 +/-2°C in M17 broth (Oxoid Ltd. 
Basingstoke, UK) supplemented with 0.5% (w/v) glucose. Lactobacillus plantarum was 
cultured statically at 37°C in MRS broth (Oxoid Ltd. Basingstoke, UK). Pseudomonas 
aeruginosa strains were propagated at 37°C with 200 rpm shaking in LB broth for routine 
growth. Escherichia coli DH5a was cultured at 37°C with 200 rpm shaking in LB broth. 
Agar plates were made by adding 1.5% (w/v) agar to the broth media.  For maintenance 
of plasmids, erythromycin (Em) was added to the growth media of E. coli and LAB strain 
at a concentration of 150 µg/mL and 6 µg/mL respectively. 
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Table 3.1 Strains and plasmids 
Strain  Description Source and/or reference 
E. coli DH5α 
 
Host for cloning: F- 80dlacZ 
M15 (lacZYA-argF) U169 
recA1 endA1hsdR17(rk-, 
mk+) phoAsupE44 -thi-1 
gyrA96 relA1 
Saltikov and Newman, 2003 
 
L. plantarum ATCC 14917 
 
Wild Type ATCC bacteriology 
collection 
L. plantarum WCFS1 
 
Wild Type Kindly provided by Dr. 
Juan Borrero at the 
University of Minnesota 
P. aeruginosa NH57388A 
 
Stable mucoid CF mouse 
sputum isolate, 
hyperproducing alginate, 
functional AHL-based QS, 
mutation in mucA. 
  
Kindly provide by Dr. 
Bryan Williams at the 
University of Minnesota 
P. aeruginosa PAO1 
ΔalgD 
 
Alginate knockout strain Kindly provided by Dr. 
Katharina Ribbeck at the 
Massachusetts Institute of 
Technology 
 
P. aeruginosa PAO26 Mucoid clinical isolate from 
cystic fibrosis patient 
Kindly provide by Dr. 
Bryan Williams at the 
University of Minnesota 
 
L. lactis subsp. cremoris 
NZ9000 
 
Plasmid-free strain, 
derivative of L. lactis 
MG1363; pepN::nisRK, non 
bacteriocin producer; EntAr 
 
Kindly provided by Dr. 
Juan Borrero at the 
University of Minnesota 
 
Plasmid  Description Source and/or reference 
pMSP3545 Emr; inducible expression 
vector carrying the nisA 
promoter and the nisR and 
nisK genes 
 
Kindly provided by Dr. 
Juan Borrero at the 
University of Minnesota 
pMG36e Emr; p32 constitutive 
promoter 
Kindly provided by Dr. 
Juan Borrero at the 
University of Minnesota 
 
pUC57-algscFv Ampr; pUC57 containing the GenScript (Piscataway, NJ) 
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alginate scFv (Alginate 
binding antibody variable 
region with linker peptide) 
synthesized by GenScript 
 
pDR111-GFPsp Ampr; pDR111 containing 
the GFPsp gene optimized 
for expression in gram 
positive bacteria 
 
Kindly provided by Dr. 
Claudia Schmidt-Dannert at 
the University of Minnesota 
pJE1 Emr; pMSP3545 containing 
the signal peptide sequence 
(cloned from L. plantarum 
14917) 
 
This study 
pJE2 Emr; pJE2 containing 
alginate scFv (synthesized 
by GenScript) and anchor 
peptide (cloned from L. 
plantarum 14917) 
 
This study 
pJEGFPsp Emr; pMSP3545 containing 
the GFPsp gene (cloned 
from pDR111-GFPsp) 
 
This study 
pJE7 Emr; pJEGFPsp containing 
the binding cassette from 
pJE2 with a RBS site in 
front of the cassette 
 
This study 
 
Table 3.2 Primer sequences 
Primer  Nucleotide sequence (5’-3’) 
PrimF-Sp(SphI)6-9 TTAGCATGCTATAAGGAGGCACTCAACATGGGGG
AGGAGCGTATGCGAAGA 
 
PrimR-Sp(SpeI)6-9 TAAGTTACTAGTTCAAGCACGACGGCGATAACC 
 
PrimF-OptalgscFv CACATGCTAAAGAAATCTTCTAGACAGTTACAGTT
ACAAGAAAGTG 
 
PrimR-OptalgscFv GGCCATGGAACTGTCAATTTCGTGCC 
 
PrimF-Anchor TTGACAGTTCCATGGCCGGTCACTGAACCAGGA 
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PrimR-Anchor(SpeI)pMSP TAAGTTACTAGTTCAAGCACGACGGCGATAACC 
 
PrimF-GFPsp(NcoI) CATGCATGCCATGGTTTCTAAAGGTGAAGAATTG 
 
PrimR-GFPsp(SphI) CCGGCATGCTTATTTATACAATTCATCCATACCAT
G 
 
a Restriction enzyme cleavage sites are underlined in the primers; RBS site shown in bold 
 
Basic genetic techniques and enzymes  
Qiagen kits were used for all purification of genomic DNA, PCR products, and 
plasmids (QIA-GEN, Hilden, Germany). Restriction enzymes, T4 DNA ligase, Taq 
polymerase, and Antarctic phosphatase were purchased from New England Biolabs 
(NEB, Beverly, MA). Taq polymerase (NEB) was used for colony PCR, and TaKaRa Ex 
Taq DNA polymerase (Clonetech) was used for PCR amplification. E. coli cells were 
made compotent according to standard protocols with some adaptations (Sambrook, 
2001), and LAB strains were made electrocompetent and transformed using a Gene 
PulserTM (Bio-Rad Laboratories, Hercules, CA) as described previously (Aukrust et al., 
1995). Primers were purchased and DNA sequencing was performed at the University of 
Minnesota Biomedical Genomics Center (Minneapolis, MN). 
Construction of plasmids 
Construction of the binding cassette 
 For a list of primers and plasmids used in this study see Table 3.1. The design 
for the binding cassette was based on previous studies (Fredriksen et al., 2010), but the 
specific construct for this work was developed during this project. The binding cassette, 
which included a signal peptide (Sp), an Alginate binding scFv (algscFv), and an anchor 
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peptide (Anchor) were PCR amplified and joined together via Gibson assembly.  The 
signal peptide and the anchor peptide were obtained from L. plantarum ATCC 14917 
genomic DNA using PrimF-Sp(SphI)6-9 and PrimR-Sp(SpeI)6-9 for the signal peptide, 
and PrimF-Anchor and PrimR-Anchor(SpeI)pMSP for amplification of the anchor 
peptide sequence.  The anchor peptide is a truncated version of lp_2578, accession no. 
YP_004890243. The algscFv binding protein sequence design included the heavy and 
light chain of the F429 mAb (F429 IGHV-D-J accession no. AY626664.1, and F429 
IGLV-J accession no. AY626662) that was developed by the Channing Laboratory (Pier 
et al, 2004). The heavy and light chains from this mAb were fused together with a linker 
peptide sequence (GGGGS3) in order to enable proper folding and display of the scFv. 
The algscFv was codon-optimized by GenScript for expression in Lactobacillus and 
synthesized by GenScript (Piscataway, NJ). GenScript originally sent this algscFv gene 
product in pUC57. PrimF-OptalgscFv and PrimR-OptalgscFv were used to amplify the 
algscFv gene from pUC57. The binding construct was cloned into pMSP3545 and 
regulated by the pNisA nisin inducible promoter.  
Construction of pJEGFPsp and pJE7 
 The GFPsp gene was provided by Dr. Claudia Schmidt-Dannert (St. Paul, MN). 
The GFPsp gene was amplified from the pDR111-GFPsp plasmid using PrimF-
GFPsp(NcoI) and PrimR-GFPsp(SphI). This PCR product was cloned into pMSP3545 
using the NcoI and SphI restriction enzyme sites, which yielded the pJEGFPsp plasmid.  
pJE7 was obtained by amplifying the binding cassette with PrimF-sp(SphI)6-9 and 
PrimR-Anchor(SpeI) and cloning this PCR product into the pJEGFPsp using the sphI and 
speI site, which yielded the pJE7 plasmid. The PrimF-sp(SphI)6-9 primer also contained 
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a RBS binding site that was identical to the RBS site that is found in the pNisA promoter 
region.  
Characterization of nisin induction 
 Overnight cultures of L. lactis (pJEGFPsp or pJE7) cells were diluted 1:100 in 5 
mL of M17+ glucose (0.5%) supplemented with 6 µg/mL erythromycin. After 2 h of 
growth at 32°C the cultures were induced with various concentrations of nisin (0 – 40 
ng/mL).  Optical density measurements (600 nm) were recorded every hour for 7 h, and 
GFP expression was measured using a fluorescent plate reader.  
Protein characterization 
 Cultures were started by adding 100 µL of an overnight culture to sterile M17 + 
glucose (0.5%) (10 mL) supplemented with 6 µg/mL erythromycin.  After 2 h of growth 
at 32°C the cultures were induced with 10 ng/mL nisin. Cells were harvested by 
centrifugation at 4,000 rpm for 10 min after an additional 4 h of growth at 32°C.  The 
supernatant was removed and the pellet was re-suspended in 10 mL of PBS (pH 7.2).  
Cells were then sonicated with a Branson 250 sonicator set at an output power of 6 for 8 
min. Sonication pulses were set to sonicate 30% of the total time (for every 3 seconds of 
sonication there was a 7 second intermission time period). Following sonication, the 
lysed cells were centrifuged at 10000 g for 10 min to remove the cell debris. The pellet 
was re-suspended in 100 µL of PBS, and the supernatant was centrifuged at 100000 g for 
30 min.  The resulting pellet, which contained the cellular membrane components, was 
re-suspended in 30 µL of PBS.  Protein concentrations were determined according to the 
Coomassie Plus TM (Bradford) Assay (Thermo Scientific, Rockford, IL).  
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 Samples were treated with BoltTM (Life technologies, Carlsbad, CA) non-reducing 
sample buffer and incubated at 70°C for 10 min. To visualize the expression and the 
location of the binding cassette product and GFP, the samples were separated on a 10% 
Bis-Tris polyacrylamide gel. Gels were then stained with coomasie for 2 h followed by a 
minimum of 3 h of de-staining with 50% methanol and 10% glacial acetic acid.  
Quantification of alginate 
 Alginate was precipitated from 1 mL aliquots taken from 5 mL P. aeruginosa 
cultures that were grown at 37°C for 48 h.  The 1 mL aliquots were centrifuged at 23,000 
X g for 30 min at 4°C.  The resulting pellet was discarded, and the supernatant was added 
to 3 mL of 99% ice-cold ethanol. The precipitate was centrifuged at 5,000 X g for 5 min 
at 4°C, and the pellet was dissolved in 0.9% saline (Hoffmann et al., 2005). 
Quantification of alginate was then carried out according to the carbazole-borate method 
developed by Knutson and Jeanes with some modifications (Knutson and Jeanes, 1968). 
Briefly, 190 µL of boric acid (100 mM) was added to the wells of a 96-well plate. An 
aliquot (30 µL) of the purified alginate sample was then added to the wells with boric 
acid and mixed by pipetting up and down twice. Carbazole solution (30 µL , 0.1% in 
ethanol) was added to the wells and mixed as before. The plate was then sealed and 
placed in a 55°C incubator for 40 min.  The resulting absorbance values were read at 530 
nm. A standard curve based on known concentrations of pure alginate (3.125 – 50 µg/mL, 
final concentration in wells) was used to determine the concentration of the unknown 
samples. 
Characterization of binding to P. aeruginosa biofilms 
P. aeruginosa growth in MultiRep reactor 
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 P. aeruginosa NH57388A and P. aeruginosa PAO26, was grown in LB (20 g/L) 
+ glycerol (1%) overnight at 37°C and 200 rpm shaking. LB media is commonly used for 
Pseudomonas alginate production, and glycerol has been found to promote alginate 
production (Wingender et al., 2001; Hoffman et al., 2005). This culture was then diluted 
1:10 in sterile LB (20 g/L) + glycerol (1%).  The channels of the MultiRep reactor (See 
Chapter 2 for description of MultiRep reactor setup) were inoculated with 4 mL of the 
diluted culture and held statically for 4 h at room temperature. Growth in the reactor was 
then carried out over a period of 6 days (48 h of flow at 0.7 ml min-1, then held static for 
48 h, followed by an additional 24 h of flow) with LB (6 g/L) + glycerol (1%).  The long 
growth period was used due to the slow growth of P. aerguinosa NH57388A. Sample 
discs were pulled from the reactor throughout this cycle to quantify the biofilm growth 
using the crystal violet assay (see chapter 2). Following the 6 days of growth in the 
MultiRep reactor, discs were removed and transferred to a 96-well plate. 
P. aeruginosa growth in 96-well plate 
 P. aeruginosa NH57388A, was grown in LB (20 g/L) + glycerol (1%) overnight 
at 37°C and 200 rpm shaking.  This culture was then diluted 1:10 in sterile LB (20 g/L) + 
glycerol (1%). 150 µL of this diluted culture was then added to the wells of a 96-well 
plate and incubated for 72 h at 35+2°C and 100 rpm shaking. After 72 h, the media was 
removed from the wells and sterile LB (20 g/L) + glycerol (1%) was added to the wells. 
This was done to supply the established biofilm with fresh media nutrients. The plate was 
incubated for an additional 24 h. P. aeruginosa (PAO1 ΔalgD) biofilms were grown as 
described for PA NH57388A except that the biofilm was grown for 24 h.  This difference 
in biofilm growth time was due to the difference in biofilm growth rates of these P. 
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aeruginosa strains. After biofilm growth, the spent media was removed from the wells 
and the wells were washed 1 X with sterile PBS (pH 7.2) to remove unattached 
planktonic cells.  
Preparation of L. lactis cells for binding studies 
L. lactis cells were prepared and induced as described in the ‘Characterization of 
nisin induction’ section of this chapter. The induced cultures were then diluted 1:3 in 
sterile M17+glucose broth supplemented with 6 µg/mL erythromycin and 10 ng/mL 
nisin. This diluted cell culture was then added to the wells of a 96-well plate that either 
had the biofilm grown on the walls of the wells, or the biofilm grown on the steel discs 
using the MultiRep reactor.  The induced L. lactis cells were exposed to the biofilm for a 
period of 3.5 h at room temperature. Discs and wells were washed a series of times (1 – 6 
X depending on the assay performed) with sterile PBS (pH 7.2) to remove unattached 
cells. The plate was then sonicated in a water bath on high for 30 min to detach the 
biofilm from the surface. The contents of the wells were then mixed using a multichannel 
pipette by pipetting up and down 2 X and swirling the pipette tips for 10 revolutions. 
Fluorescence microscopy 
 Steel discs treated as described in the previous section (washed 5 X with PBS) 
were viewed under a conventional epifluorescence microscope (Olympus BX51, Center 
Valley, PA) with an Xcite light source. An FITC filter source was used, and the study 
was performed in duplicate. Multiple images were taken of each surface, and 
representative images were chosen for display in the results section. 
Quantitative binding assay 
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 After L. lactis exposure to PA biofilms and washing (as described above), the 
plate was sonicated in a water bath on high for 30 min to detach the biofilm from the 
surface. The contents of the wells were then mixed using a multichannel pipette by 
pipetting up and down 2 X and swirling the pipette tips for 10 revolutions. For wells that 
contained the steel discs, aliquots of the re-suspended cell solution were transferred to 
clean wells for analysis. Relative fluorescent units were measured using a fluorescent 
plate reader (Top read, Excitation 485 nm/Emission 528 nm, sensitivity 70). To 
determine the percentage of fluorescence retained after washing, the fluorescence 
measured for each test well was divided by the average initial fluorescence measurement 
for each GFP producing strain of L. lactis.  
Preliminary testing of LAB strains against P. aeruginosa biofilms 
Lactobacillus sp. supernatant and cell culture study 
P. aeruginosa (PAO26) biofilms were grown at 37°C in TSB for 24 h in a 96-well 
plate at 90 rpm. The planktonic PAO26 culture was removed from the wells of the 96-
well plate. Overnight cultures of L. plantarum strains (WCFS1, NC8, 14917, and 10241) 
were grown at 37°C in MRS. To obtain the supernatants, cultures were centrifuged at 
4000 rpm for 10 min.  A portion of each supernatant was pH neutralized (pH 7) with 
NaOH. The un-neutralized supernatant from each sample was acidic (pH ~ 3.7). 
Following neutralization, the supernatants were filter sterilized. The supernatants were 
added to the wells containing the biofilms in triplicate with final concentrations ranging 
from 5% - 25% (total well volume was 160 µL).  The base media in the wells was TSB 
media.  The supernatants were exposed to the biofilms for 18-24 hrs at 37°C. For the cell 
culture study, a 2 µL aliquot from each culture was used to inoculate the wells containing 
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the PAO26 biofilms and fresh TSB (performed in quadruplicates). The plate was then 
incubated for an additional 24 h at 37°C.  Following the supernatant and cell culture 
treatments, the crystal violet assay was performed for each test.  
L. plantarum WCFS1 and tobramycin study against P. aeruginosa biofilms 
 
 P. aeruginosa (PAO26) biofilms were grown at 37°C in TSB for 24 h in a 96-well 
plate at 90 rpm. The planktonic PAO26 culture was removed from the wells of the 96-
well plate. Overnight cultures of L. plantarum WCFS1 was grown at 37°C in MRS. An 
aliquot (5 µL) of the WCFS1 cell culture was then added to the wells containing the 
biofilms and fresh TSB. The plate was incubated overnight, and the following day wells 
were treated with tobramycin (0 – 360 µg/mL) for an additional 24 h.  Following the 
treatments, CFU enumeration was performed as described in the materials and methods 
section of chapter 2 with one exception. TSB plates were supplemented with 5 µg/mL 
chloramphenicol to inhibit the growth of L. plantarum (WCFS1). Prior to performing this 
test, P. aeruginosa verified to be resistant to this concentration of chloramphenicol.  
 
Results and Discussion 
Characterization of the engineered L. lactis strain 
Genetic construction of the binding cassette 
 The genetic construct for the binding cassette (scFv F429 DNA sequence fused 
between the signal peptide and the anchor peptide of lp_2578 sequences) was 
successfully made and verified by sequencing (Figure 3.2). Initially, the signal peptide 
was cloned into pMG236e following the strong constitutive p32 promoter. Then the 
algscFv fragment and the anchor peptide PCR products were fused after the signal 
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peptide using the Gibson assembly method. However, this failed to produce E. coli DH5a 
clones that incorporated the entire binding cassette. A possible reason for this issue is that 
the constitutively expressed proteins were toxic to E. coli.  The binding cassette; 
however, was obtained by using the Gibson assembly product and PCR amplifying the 
entire cassette with PrimF-Sp and PrimR-Anchor primers. This construct was then cloned 
into the pMSP3545 vector after the nisin inducible pNisA promoter, and sequenced to 
verify proper gene orientation and sequence integrity.  Any additional cloning was 
carried out in the nisin inducible pMSP3545 vector to avoid any toxicity issues in E. coli.   
 
Figure 3.2. Binding cassette construct. pNisA, nisin inducible promoter within the 
pMSP3545 vector. SP, signal peptide sequence. VH, heavy chain variable region 
sequence. VL, light chain variable region sequence. Anchor, sortase dependent cell 
membrane protein containing a hydrophobic region N terminally to the LPQTXE motif.  
 
Characterization of nisin induction  
Due to the difficulty of direct expression characterization of the binding protein 
construct, GFPsp was added to the vector as a reporter protein.  The expression of the 
GFPsp gene is under the regulation of the same promoter as the binding cassette.  To gain 
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an understanding of the optimal nisin concentration necessary for expression of these 
proteins in L. lactis, a study was performed with a range of nisin concentrations (0 – 40 
ng/mL)(Figure 3. 3).  The GFP expression from each of these cultures was measured 
using a fluorescent plate reader, and compared to the cell density after 6 hours of 
incubation after the time of induction. The optimal nisin induction concentration falls 
between 5 and 20 ng/mL, and higher concentrations (40 ng/mL) inhibited growth of the 
cultures.  10 ng/mL was chosen as the induction concentration going forward, which is in 
agreement with previous work (Desmond et al., 2004).     
 
Figure 3.3.  Effect of nisin concentration on GFP expression and cell density for L. lactis 
(pJE7).  
 
Characterization of protein expression  
 
The scFv F429 was successfully fused to the SDP lp_2578 and displayed on the 
cell membrane of L. lactis. Cytoplasmic and cell membrane fractions of both un-induced 
(regular font) and induced (bold font) L. lactis cultures containing both GFPsp and the 
binding cassette were separated and prepared. The proteins from these cell fractions were 
then compared via LDS polyacrylamide gel electrophoresis (Figure 3.4). The results 
indicate that GFP (expected size 28 kDa) was found only in the cytoplasmic fraction 
0	  0.2	  
0.4	  0.6	  
0.8	  1	  
1.2	  
0	  200	  
400	  600	  
800	  1000	  
1200	  1400	  
1600	  1800	  
0	   5	   10	   20	   40	  
Ab
s.
	  O
D
60
0	  
Re
la
ti
ve
	  +l
uo
re
sc
en
ce
	  u
ni
t	  (
RF
U
)	  
Nisin	  (ng/mL)	  RFU	  (left	  axis)	   OD600	  (right	  axis)	  
	  
47	  
(Figure 3.4A), which is expected due to the fact that there is no signal peptide attached to 
the GFP for secretion outside the cell.  The binding cassette protein (expected size 47.23 
kDa) was found primarily in the cell membrane fraction (Figure 3.4B). The binding 
cassette proteins were not found in the culture supernatant (data not shown), indicating 
that the scFv F429 fused to the lp_2578 SDP was anchored to the peptidoglycan of the 
cell wall of the L. lactis cells. The more intense band seen around 62 kDa in the un-
induced cell membrane faction (Figure 3.4A) is most likely due to a difference in total 
protein concentration between the un-induced and induced cultures. 
                A                B 
      
 
Figure 3.4.  LDS-PAGE separation of membrane fractions. (A) cytoplasmic fractions of 
cellular components (pellet from 10000 x g centrifuge step). (B) Cell membrane fractions 
( pellet from 100000 x g centrifuge step). Un-induced cultures are in regular font. 
Induced cultures are shown in bold font. Expected size of GFP - 28 kDa; Expected size of 
binding cassette protein - 47.23 kDa. 
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Attachment to Pseudomonas aeruginosa biofilms 
Next, to determine if the engineered cells could bind to P. aeruginosa alginate-
containing biofilms, the L. lactis cells expressing GFPsp alone or GPFsp and the binding 
cassette were exposed to P. aeruginosa NH57388A cultivated as biofilms on steel discs, 
washed five times, and viewed with a epifluorescence microscope using an FITC filter 
(Figure 3.5). Samples were prepared in duplicate, and the images were taken of areas 
that represented the majority of the sample surface. The images show that a higher 
number of cells expressing the binding cassette (Figure 3.5B) were recovered than cells 
that did not have the ability to make the binding cassette protein (Figure 3.5A). This 
indicates that the binding cassette protein was not only expressed on the cell membrane 
of L. lactis, but also enhanced binding to P. aeruginosa alginate producing biofilms. As 
mentioned previously, not all strains of P. aeruginosa produce alginate; therefore, it was 
important to verify that P. aeruginosa NH57388A does indeed produce alginate prior to 
performing binding studies. By performing the carbazole assay (Knutson and Jeanes, 
1968), the amount of alginate produced by P. aeruginosa NH57388A biofilms grown in a 
96 well plate was determined to be approximately 12 µg/well. See Figure S2 for standard 
carbazole curve. 
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A      B 
 
Figure 3.5. Characterization of attachment to P. aeruginosa NH57388A biofilms on steel 
discs. Biofilms were grown on steel discs in the MultiRep reactor. L. lactis (pJEGFPsp – 
GFP only) (A) and L. lactis (pJE7 – GFP + bindng cassette) (B) were exposed to the 
biofilms and washed prior to imaging.  Images were taken with a fluorescent microscope 
at 100x magnification.   
 
The fluorescent microscope images qualitatively indicate that the engineered 
strain of L. lactis does have enhanced binding to biofilm structures containing alginate. 
Next, a quantitative study to analyze the binding of the engineered L. lactis strain to the 
biofilms was designed. Biofilms of both the alginate producing strain (PA NH57388A) 
and a non-alginate producing strain (PAO1 ΔalgD) were grown on the well surfaces of a 
96-well plate.  L. lactis cells expressing GFP only, or GFP and the binding cassette were 
then exposed to the biofilms for 3.5 h, washed, and the percentage of fluorescence 
retained was determined by dividing by the starting fluorescence of each culture. This 
calculation was performed because the starting fluorescence of the GFP only and the 
GFP-binding cassette strains had different initial fluorescence expression. The percentage 
of fluorescence retained after exposure to the alginate-containing biofilms is shown in 
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Figure 3.6A, while the results after exposure to the non-alginate producing strain are 
shown in Figure 3.6B. The results indicate that there was a significant difference in 
binding observed between the L. lactis strain that contained the binding cassette and the 
strain that expressed GFP alone. A student’s t-test was performed to compare the 
statistical significance of the means obtained for each comparison.  It is interesting to 
note that as the number of washes increases in Figure 3.6A, the statistical significance 
increases between the percent fluorescence retained for the strain that has the binding 
cassette and the GFP-only strain. Additionally, when the GFP-only and GFP-binding 
cassette strains of L. lactis are exposed to biofilms that do not contain alginate, the 
difference between the two strains is lowered as the number of washes increases (Figure 
3.6B). Therefore, it appears that expression of the binding cassette in L. lactis did enable 
specific binding to P. aeruginosa biofilms that contain alginate. 
A                 B 
       
Figure 3.6. Quantitative binding assay – biofilm grown in 96 well plate. (A) P. 
aeruginosa NH57388A - the alginate producing strain and (B) P. aeruginosa (PAO1 
ΔAlgD) - the alginate knockout strain were grown on the well surfaces of a 96 well plate 
and exposed to L. lactis strains (pJEGFPsp – GFPsp only) or (pJE7 – GFPsp + binding 
cassette).  The cells were washed a number of times and the percentage of fluorescence 
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retained was calculated. (*) Indicates statistical significance between GFP only and GFP 
+ binding cassette for 1 wash (p < 0.05). (**) Indicates statistical significance between 
GFP only and GFP + binding cassette for 3 washes (p < 0.01). Error bars are based on n = 
8.  
 
 An additional quantitative study was performed with the P. aeruginosa biofilms 
grown on steel discs in the MultiRep reactor. For this study, both the percent fluorescence 
retained and the CFU/disc recovered was determined for each group studied (Figure 3.7). 
The results from this study again indicated that there was a statistically significant 
difference between the GFP-only and GFP-binding cassette cells recovered.  It is 
important to note that for the CFU/disc determination, the L. lactis cells recovered were 
diluted and plated onto MRS agar. Normally, L. lactis is grown on M17 + glucose media, 
but MRS was chosen because P. aeruginosa does not grow on this media.  The L. lactis 
did not grow as quickly on the MRS media, and the colonies were smaller.  
A            B 
   
  
 
Figure 3.7. Quatitative binding assay – biofilm grown in MultiRep reactor. P. aeruginosa 
NH57388A was grown on steel discs in the MultiRep reactor and exposed to L. lactis 
(pJEGFPsp – GFP only) or L. lactis (pJE7 – GFP + binding cassette).  Left graph (A) 
shows the percentage of fluorescence retained by the L. lactis cells. Right graph (B) 
shows CFU of L. lactis/disc recovered. (*) Indicates statistical significance between GFP 
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only and GFP + binding cassette (p < 0.05). (***) Indicates statistical significance 
between GFP only and GFP + binding cassette for 3 washes (p < 0.001). Error bars are 
based on n = 6 for (A), and n = 4 for (B). 
 
Growth rate of induced L. lactis strains 
 
 Next, a study was performed to determine the effect that expression of these 
proteins may have on L. lactis growth over time. Three strains of L. lactis were 
compared: L. lactis Wt, L. lactis pJEGFPsp (GFP), and L. lactis pJE7 (GFP-binding 
cassette) over a total time of 7 h. This time period was chosen because this was the 
normal time of culture prior to harvest for binding studies. After 2 hours of growth, 
protein expression was induced with nisin (10 ng/mL). The expression of these 
recombinant proteins in L. lactis does appear to have a slight effect on growth rate 
initially (Figure 3.8).  However, there does not appear to be a significant difference 
between the growth rate of the GFP-only and the GFP-binding cassette strain.  
 
Figure 3.8. Growth rate of L. lactis strains over time. LL = L. lactis, pJEGFPsp (GFP 
expression only), pJE7 (GFP + binding cassette). Each strain was induced with nisin (10 
ng/mL) at the 2 h time point.  
 
 
 
 
 
 
0	  
0.5	  
1	  
1.5	  
2	  
2.5	  
0	   1	   2	   3	   4	   5	   6	   7	  
Ab
s.
	  O
D
60
0	  
Time	  (hr.)	  
LL	  wt	  LL	  pJEGFPsp	  LL	  pJE7	  
	  
53	  
Preliminary testing of LAB strains against P. aeruginosa biofilms 
 The feasibility of engineering a LAB strain to attach to biofilm structures of P. 
aeruginosa was demonstrated. The next step for this project is to develop the anti-biofilm 
component. The biofilm attachment studies were done in L. lactis due to the ease of 
genetic manipulation, and because the nisin inducible system is well characterized in this 
organism (Mierau and Kleerebezem, 2005). However, the next phase of this project may 
involve the implementation of the binding components into a different LAB strain with 
useful enzymatic, inhibitory or immune-modulation activities such as an L. plantarum 
spp. Native L. plantarum strains have been found previously to have anti-biofilm 
properties (Ramos et al., 2012).  Preliminary testing with a number of wild-type L. 
plantarum strains was performed to determine which strain, if any, has a natural 
inhibitory effect on P. aeruginosa biofilms.  In this study, both the supernatants (Figure 
3.9) and the cell cultures (Figure 3.10) of four L. plantarum strains (WCFS1, NC8, 
14917, and 10241) were tested against P. aeruginosa biofilms. Overnight cultures of each 
of the L. plantarum strains were prepared, and either the supernatants (untreated or pH 
neutralized), or the cell cultures were added to pre-formed P. aeruginosa PAO26 biofilms 
and the amount of biofilm removed was analyzed using the crystal violet assay.  For the 
supernatant study, it was hypothesized that the low pH of L. plantarum cultures (pH ~ 
3.7) may lead to biofilm removal because low pH has been found to decrease P. 
aeruginosa biofilm production (Hostacká et al., 2010).  To test this hypothesis, 
neutralized or un-neutralized supernatants were exposed to preformed biofilms and 
analyzed.  In each of these studies in this section, P. aeruginosa PAO26 (A mucoid 
isolate from the lungs of a cystic fibrosis patient) was used instead of P. aeruginosa 
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NH57388A because this strain formed robust biofilms more quickly than the NH57388A 
strain.   
           A             B 
 
Figure 3.9. L. plantarum supernatant effect on P. aeruginosa PAO26 biofilms. Biofilms 
were grown for 24 h, then treated with raw, or neutralized supernatants from L. 
plantarum cultures for an additional 24 h. Following treatment, the crystal violet assay 
was performed to quantify the biofilm remaining. (A) is 5% supernatant, and (B) is 25% 
supernatant concentration in the final test volume. MRS (pH 6.5) is the broth that the L. 
plantarum strains were grown in. Error bars are based on n = 3.  
 
 
 The results from these studies indicate that some of the L. plantarum cells may 
have the ability to degrade or remove P. aeruginosa biofilm structures.  Interestingly, the 
neutralized supernatants, for some of the strains, appeared to have a greater ability to 
remove P. aeruginosa biofilm than the acidic supernatants. This indicates that the low pH 
was not the primary mechanism of biofilm removal, and there may be products that these 
organisms make that have a P. aeruginosa biofilm removal effect under neutral pH 
conditions. The results from the L. plantarum cell culture study (Figure 3.10) indicate 
that some of the L. plantarum cells, when grown in the presence of P. aeruginosa 
biofilms, may also have a biofilm removal effect. It was important to perform these initial 
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tests, because the addition of the L. plantarum cells to the biofilm cultures could have 
enhanced biofilm growth, which would have been less than ideal for our purposes. 
However, it appears that this is not the case, and that some of these strains may be good 
candidates to choose for further development.    
  
Figure 3.10. Removal of P. aeruginosa PAO26 biofilms with L. plantarum cell cultures. 
(A) Biofilms were grown for 24 h, and treated with 2 µL of L. plantarum cell culture for 
an additional 24 h (Error bars based on n = 3). (B) Additional testing of biofilm removal 
with L. plantarum WCFS1 using different starting volumes of L. plantarum culture, final 
volume in each well was 160 uL (Error bars based on n = 4). 
 
 
 Based on the results of the study comparing the biofilm removal ability of 
multiple L. plantarum strains, strain WCFS1 was chosen for further testing.  One future 
application of our engineered LAB strain may be to enhance the efficacy of antibiotic 
treatments against biofilms. A study was designed to gain an initial understanding of the 
impact L. plantarum WCFS1 cell cultures may have on the antimicrobial activity of 
tobramycin against P. aeruginosa biofilms. Tobramycin is a commonly used antibiotic 
for P. aeruginosa infections, but along with many of the treatment options for this 
pathogen, is much less effective against the biofilm-associated cells (Hill et al., 2005).  
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For this study, P. aeruginosa PAO26 was grown on the well surfaces of a 96-well plate.  
The biofilms were then treated with L. plantarum WCFS1 cell cultures overnight, 
followed by treatment with tobramycin (120 or 360 µg/mL). The results in Figure 3.11A 
indicate that the pre-treatment of P. aeruginosa biofilms with L. plantarum cell cultures 
may slightly increase the activity of tobramycin against P. aeruginosa biofilms. Although 
this difference was small in this study, further testing should be completed with higher 
replication.  
Next, a study was performed to determine the effect that the biofilm growth 
method has on the antibiotic resistance of P. aeruginosa PAO26. This study was 
performed against biofilms grown in a 96-well plate and biofilms grown in the MultiRep 
reactor on steel discs (Figure 3.11B).  The results indicated that the biofilms grown using 
the MultiRep reactor were more resistant to the tobramycin treatment; and therefore, the 
MultiRep reactor may be a better system for biofilm growth for future efficacy testing.  
Additional testing was performed with alginate lyase, but the results were inconclusive at 
this point and require further testing. 
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                   A                                                                     B 
   
Figure 3.11. Tobramycin and L. plantarum cell cultures against P. aeruginosa PAO26 
biofilms. (A) shows the effect that tobramycin, in combination with L. plantarum, has on 
P. aeruginosa biofilm cell viability. (B) Shows a comparison of tobramycin activity 
against P. aeruginosa biofilms grown in the MultiRep reactor or a 96-well plate. 
    
 
 
 
Conclusion 
 Due to the synergistic effect of antibiotic resistance and a dearth of new 
antibiotics entering the pipeline, there is a global need for a new paradigm in infection 
prevention strategies. Biofilms have been highlighted as one of the major contributing 
factors for chronic bacterial infections that are essentially untreatable in some cases. Here 
we designed a strain of L. lactis that displays a heterologous alginate-binding scFv on its 
cell wall by anchoring it to a native LAB sortase dependent cell membrane protein. The 
expression of these proteins was not only directed and anchored to the cell membrane of 
the L. lactis cells, but they also increased the ability of this organism to attach to P. 
aeruginosa biofilms. This is a novel strategy that can be added to the toolbox for 
development of microbial therapeutics that deliver drugs to the precise location of 
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pathogenic biofilms. Indeed, this project has demonstrated the feasibility of this 
technology for future implementation against additional microbial pathogens that form 
persistent biofilms. Preliminary testing was also performed to characterize the anti-
biofilm properties of multiple wild-type LAB strains in order to choose the most effective 
strains for further development. L. plantarum WCFS1 appears to hold promise for further 
development, not only because it appears to naturally have the ability to remove P. 
aeruginosa biofilms, but it has also been found to modulate the human immune system 
(Remus et al., 2013).  
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CHAPTER 4 
FUTURE DIRECTIONS AND CONCLUSIONS 
 Before 1673, the world did not know that microorganisms even existed. The field 
of microbiology was then born through Anton van Leeuwenhoek’s discovery of 
microorganisms.  It is interesting to consider the successive advancement from the 
discovery of microbes, to the realization that they cause infections (Germ theory), to the 
development of antibiotics for their control. Today, an increasing number of microbial 
pathogens are resistant to our treatment methods, which has forced us on a global scale to 
re-evaluate our current infection control strategies. The WHO states, “A post-antibiotic 
era, in which common infections and minor injuries can kill, far from being an 
apocalyptic fantasy, is instead a very real possibility for the 21st century.” (WHO, 2014). 
 The significance of biofilms in microbial pathogenesis is now firmly established. 
The understanding that biofilm-associated microbes are much more resistant to 
antimicrobial treatment than free-living cells underscores the need for treatments that are 
effective against these organisms in their biofilm state (Nickel, 1985).  To aid in this 
effort we have developed the MultiRep biofilm reactor that can be used for efficient 
biofilm testing, and a microbial therapeutic strategy that targets biofilms. Each of these 
developments holds great promise for future work and applications.  
  The MultiRep reactor enables the high-throughput growth of biofilms at the air-
water interface under laminar flow conditions. This reactor increases biofilm testing 
efficiency by lowering the time and cost per coupon, and increases the reproducibility of 
biofilm growth compared to the drip flow reactor that is currently available commercially 
(Goeres, 2009). Each well in this reactor was designed to accommodate coupons that can 
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be transferred to a 96-well plate for efficient subsequent testing of anti-biofilm products. 
Testing with P. aeruginosa PAO26 biofilms grown in a 96-well plate or the MultiRep 
reactor indicated that the biofilms grown in the reactor were more resistant to tobramycin. 
This highlights the importance of the biofilm growth method used prior to antimicrobial 
testing. For in vitro biofilm testing, the growth method that most closely represents the 
natural environment must be used in order to have the most accurate forecast of the 
antimicrobial activity.  
 One near term direct application of this reactor will involve the growth of C. 
albicans biofilms for further characterization of anti-fungal natural products that were 
found to have synergist activity with copper against this pathogen. Briefly, a 
Streptomyces sp. bacterium (CES-254) was isolated from the Soudan mine in northern 
Minnesota, and was found to have anti-fungal activity. Further testing indicated that this 
organism produced a suite of compounds that are synergistic with copper against C. 
albicans planktonic cells. Preliminary testing against C. albicans biofilms grown on steel 
discs in a 96-well plate indicated that this synergy might also be effective against this 
organism in the biofilm state (Figure 4.1). Nocardomine was identified as one of the 
primary synergistic components with copper against these biofilms. Additional activity 
appears to be present; however, the chemical identity(s) is still being characterized.  
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Figure 4.1. CES-254 supernatant and CuSO4 activity against C. albicans biofilms. 
Biofilms were grown in a 96-well plate for 24 hrs on steel discs. The discs were then 
transferred to clean wells, washed, and treated with CuSO4 (1mM) and CES-254 
supernatant overnight. The effect on C. albicans cell viability was determined using the 
XTT assay.  
 
 This novel activity against C. albicans biofilms is important, because the 
treatment options against clinically relevant fungi are very limited.  Fluconazole is one of 
the primary treatment options for fungal infections, but many strains are developing 
resistance (CDC, 2013). Combination therapies such as the one described above, could 
lead to new treatment options against these resistant pathogens. However, further testing 
is required, and the MultiRep reactor will be an important tool for further characterization 
of this activity. This is an example of the potential for this reactor to be used in the 
development of a wide-range of anti-biofilm therapies.  
 In addition to the MultiRep reactor, we developed a probiotic bacterial strain that 
is capable of binding to specific biofilm structures. This was accomplished by 
engineering a strain of L. lactis to display a heterologous alginate-binding scFv on its cell 
wall by anchoring it to a native LAB sortase dependent cell membrane protein. 
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Preliminary testing was also performed to characterize the anti-biofilm properties of 
native LAB strains that may be used for the next phase of this project that focuses on 
anti-biofilm strategies. Biofilm degrading enzymes such as alginate lyase, DNase, or 
dispersin B could be heterologously expressed and deployed by our strain once it has 
attached to the biofilm structures.  Expression of antimicrobial peptides could also be 
employed to aid in killing of the pathogenic cells once the biofilm has been degraded.  
Yet another strategy could be to deliver quorum quenching enzymes, or signaling 
peptides that reduce antibiotic-resistance transfer among cells in a particular biofilm.  
The ability to direct the attachment of a probiotic organism to biofilm structures 
has a wide-range of potential future applications. First, the most straightforward future 
work will be to demonstrate the adaptability of this model system. In our system, the 
binding protein (scFv F429) can easily be substituted with another protein of interest.  
Therefore, different proteins that bind to other components of biofilms could be utilized.  
This means that virtually any other organism that forms a biofilm, and has a unique 
component for attachment, could be targeted. Second, the ability to direct the attachment 
of a probiotic organism to alginate could be useful in biocatalysis. Polymer matrices 
composed of agar, polyacrylamide, chitin, or alginate are commonly used as whole-cell 
entrapment/immobilization agents in biocatalysis (Robinson, 1997).  It has been noted 
that this method is limited due to the transport of substrates through the matrix.  If the 
cells can be immobilized on a monolayer of the substance, the reaction efficacy would 
theoretically increase because the adsorbed cells would have more direct contact with the 
substrates. The ability to immobilize cells onto chitin by display of a chitin-binding 
domain on the cell membrane of E. coli (Wang and Chao, 2006) and L. lactis (Simsek, 
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2013) has already been demonstrated. However, immobilization onto alginate is yet to be 
demonstrated. Third, this system could be used to enhance biofilm growth for application 
in bioremediation of toxic chemicals from wastewater.  And finally, this system could be 
used for biofilm diagnostic purposes. Biophotonic imaging is used to study 
bioluminescent bacteria in vivo, and allows the researchers to continually monitor biofilm 
infections in animals without disrupting the biofilm over the course of the disease 
(Kadurugamuwa and Francis, 2008).  Our system could potentially be used in this fashion 
to diagnose biofilm infections in humans.  The fluorescent probiotic cells that bind to 
specific biofilms could be deployed to identify the pathogen and the location of the 
biofilms in the host.  
In this thesis, a novel reactor for biofilm testing was designed and a new 
antimicrobial therapeutic strategy that targets microbial biofilms was developed.  Each of 
these developments is important because they hold great potential as valuable tools in the 
overarching goal of combating resistant microbial biofilms. 
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APPENDIX 
 
Figure S1. Correlation of XTT absorbance to P. aeruginosa CFU enumeration recovered. The 
XTT absorbance appears to be sensitive down to 100 CFU.  
 
 
Figure S2. Carbazole standard curve.  
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